Laurie Letvak

Bierer on Clinical Reserach

I have often thought of what I – or my elderly mother or uninformed nephew—would wish to know before deciding about participation in clinical research, but it is nearly impossible to narrow the desired information to the one most important point.  On the one hand, what any individual needs to – or wishes to – know will differ and be filtered through their personal and health situation, life experiences, nature and character. On the other hand, this is because the decision is, at its core, a nuanced choice that involves a balance between often competing factors.

Hinkley on Clinical Research

Participating in a clinical research study is a selfless act.  Perhaps there will be personal benefit from participating in a clinical trial, but it’s not guaranteed.  Every year individuals decide to advance scientific knowledge and available medical therapies by volunteering to participate in clinical research.  By definition clinical research involves uncertainty and I can only imagine how that must feel.  It can’t be easy.  As a clinical researcher I am extremely grateful for your bravery and selflessness.  You truly are a medical hero…to me and to others.

Terri Hinkley

Hohman on Clinical Research

It takes years for even the most promising experimental drugs to transition through laboratory development, clinical trials, and FDA evaluation in order to reach patients. FDA, collaborating with advocacy organizations and industry, has implemented numerous measures to accelerate drug development and evaluation.

Ryan Hohman

Hardi on Clinical Research

Participating in clinical research is very important. It helps us develop new medicines, potentially helps the patient’s own condition, and contributes to our knowledge about disease. Without volunteer participation, therapeutic improvement would not be possible.

Robert Hardi

Sandoval on clinical research

When talking with a patient, we should ALWAYS keep in mind the three principles of the Belmont Report. A patient must understand that they can discontinue study participation without negative repercussions from the principal investigator, or taken out if it becomes unsafe for the patient; what kind of patients and populations can and cannot participate; and what is the benefit if any. This simplistic approach if done correctly, by a study staff member should cover almost everything a patient needs to know.

Fabian Sandoval


Subscribe to PhRMA RSS